| Brentuximab Vedotin studied in …STUDIED_INderived167 of 167show fewer |
|---|
| → studied in | NCT05675410Phase 3 · recruiting A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04561206Phase 2 · recruiting Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03233347Phase 2 · active not recruiting Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03517137Phase 2 · active not recruiting Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05039073Phase 2 · recruiting Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03007030Phase 2 · active not recruiting Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery · 167 trials list this drug (45 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113500Phase 2 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma · 167 trials list this drug (45 active) | — | — | Adult T-Cell Leukemia/Lymphoma,Anaplastic Large Cell Lymphoma, ALK-Negative,Anaplastic Large Cell Lymphoma, ALK-Positive+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05922904Phase 2 · active not recruiting PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07275216Phase 2 · recruiting Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01896999Phase 1/Phase 2 · active not recruiting Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03719105early Phase 1 · recruiting Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma · 167 trials list this drug (45 active) | — | — | Aggressive NK-Cell Leukemia,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02227199Phase 1/Phase 2 · completed Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03409432Phase 2 · completed Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Lymphomatoid Papulosis,Primary Cutaneous Anaplastic Large Cell Lymphoma,Primary Cutaneous T-Cell Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04569032Phase 2 · completed A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression · 167 trials list this drug (45 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03907488Phase 3 · active not recruiting Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma,Lymphocyte-Rich Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02166463Phase 3 · active not recruiting Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Childhood Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03264131Phase 2 · completed BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma · 167 trials list this drug (45 active) | — | — | Lymphoma,Adult T-Cell Leukemia/Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05357794Phase 2 · recruiting Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides · 167 trials list this drug (45 active) | — | — | Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717580Phase 2 · not yet recruiting Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) · 167 trials list this drug (45 active) | — | — | Primary Cutaneous Anaplastic Large Cell Lymphoma,Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404283Phase 3 · active not recruiting Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL · 167 trials list this drug (45 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01352520Phase 2 · active not recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) · 167 trials list this drug (45 active) | — | — | Lymphoma,Cutaneous Lymphoma,Lymphomatoid Papulosis+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04685616Phase 3 · recruiting Brentuximab Vedotin in Early Stage Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07572123Phase 2/Phase 3 · not yet recruiting Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04609566Phase 2 · completed Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors · 167 trials list this drug (45 active) | — | — | Melanoma,Head and Neck Squamous Cell Carcinoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04587687Phase 2 · recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma · 167 trials list this drug (45 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01657331Phase 1/Phase 2 · completed Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03755804Phase 2 · active not recruiting Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05414500Phase 1 · suspended Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides · 167 trials list this drug (45 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05673785Phase 2 · active not recruiting A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05313243Phase 2 · recruiting Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma · 167 trials list this drug (45 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01868451NA · completed Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01476410Phase 2 · completed Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Adult Hodgkin Lymphoma,Adult Mixed Cellularity Classic Hodgkin Lymphoma,Adult Nodular Sclerosis Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07013565Phase 2 · recruiting Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05404945Phase 2 · active not recruiting Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01703949Phase 2 · active not recruiting Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01920932Phase 2 · active not recruiting Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Childhood Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03057795Phase 2 · active not recruiting Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06377566Phase 2 · recruiting A Study of BV-AVD in People With Bulky Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05481437recruiting A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03587844Phase 2 · recruiting Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients · 167 trials list this drug (45 active) | — | — | Lymphomatoid Papulosis,Mycosis Fungoides,Sezary Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06563245Phase 2/Phase 3 · recruiting Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03652441Phase 2 · completed Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01712490Phase 3 · completed A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06831370Phase 4 · recruiting A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04745949Phase 2 · recruiting PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02684292Phase 3 · completed Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05180097Phase 2 · recruiting Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07258680Phase 3 · enrolling by invitation BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas · 167 trials list this drug (45 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02588651Phase 2 · completed A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) · 167 trials list this drug (45 active) | — | — | Adult T-Cell Leukemia/Lymphoma,T-Cell Non-Hodgkin Lymphoma,Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02979522Phase 1/Phase 2 · active not recruiting A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07002216Phase 2 · recruiting BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01508312Phase 2 · completed Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01909934Phase 4 · completed Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05442554Phase 4 · completed A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma · 167 trials list this drug (45 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07178457Phase 3 · not yet recruiting Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance · 167 trials list this drug (45 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02758717Phase 2 · active not recruiting Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03646123Phase 2 · terminated Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01771107Phase 1/Phase 2 · completed Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | AIDS-Related Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02734771Phase 2 · active not recruiting A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) · 167 trials list this drug (45 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02616965Phase 1 · completed A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma · 167 trials list this drug (45 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03187210Phase 1/Phase 2 · suspended Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02744612Phase 2 · completed Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05595447Phase 2/Phase 3 · recruiting Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma,Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927769Phase 2 · completed A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04254107Phase 1 · terminated A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer · 167 trials list this drug (45 active) | — | — | Cutaneous Melanoma,Classic Hodgkin Lymphoma,Gastric Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06761911Phase 4 · not yet recruiting BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03712202Phase 2 · active not recruiting Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma,Lymphocyte-Rich Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04213209completed Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02388490Phase 2 · completed Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02191930Phase 2 · completed Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03729609completed Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma" · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03217643Phase 2 · completed CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. · 167 trials list this drug (45 active) | — | — | Enteropathy-Associated T-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01716806Phase 2 · completed A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01492088Phase 1/Phase 2 · completed Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02661503Phase 3 · unknown HD21 for Advanced Stages · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01979536Phase 2 · completed Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05711628Phase 3 · withdrawn A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03013933Phase 1 · completed Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06201507Phase 2 · unknown BV-AVD-R Treatment Children Hodgkin's Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03138499Phase 3 · terminated A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06186986Phase 3 · unknown CD30 Imaging in Diffuse Large B-cell Lymphoma · 167 trials list this drug (45 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02398240Phase 2 · completed Brentuximab for Newly Diagnosed Hodgkin Disease · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03947255Phase 2 · terminated A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma,Hodgkin Lymphoma,Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02096042Phase 1/Phase 2 · terminated Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) · 167 trials list this drug (45 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04795869Phase 2 · withdrawn Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Hepatosplenic T-Cell Lymphoma,Subcutaneous Panniculitis-Like T-Cell Lymphoma,Follicular Helper T-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02581631Phase 1/Phase 2 · completed An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04334174Phase 2 · withdrawn Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas · 167 trials list this drug (45 active) | — | — | T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02572167Phase 1/Phase 2 · completed A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02098512Phase 1/Phase 2 · unknown Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02292979Phase 2 · completed Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04138875Phase 2 · withdrawn A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) · 167 trials list this drug (45 active) | — | — | Lymphocytic Neoplasm,Polymorphic PTLD,Florid Follicular Hyperplasia PTLD+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03302728Phase 1 · completed Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02497131Phase 2 · completed Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02462538Phase 1/Phase 2 · terminated Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02086604Phase 1 · completed Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05243693Phase 2 · unknown Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01578967NA · completed Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02686346Phase 1/Phase 2 · completed Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01777152Phase 3 · completed ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma,Non-Hodgkin Lymphoma,T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01780662Phase 1/Phase 2 · completed Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Adult Hodgkin Lymphoma,Childhood Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01805037Phase 1/Phase 2 · terminated Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma,Hairy Cell Leukemia,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05006664Phase 2 · unknown Brentuximab Vedotin in Combination With CHEP in Patient With PTCL · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02298283Phase 2 · completed Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02499627Phase 2 · terminated Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01100502Phase 3 · completed A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01990534Phase 4 · completed A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02939014Phase 2 · completed Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01578499Phase 3 · completed A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) · 167 trials list this drug (45 active) | — | — | Primary Cutaneous Anaplastic Large Cell Lymphoma,Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Mycosis Fungoides | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01994850Phase 1/Phase 2 · completed Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02227433Phase 2 · completed Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease. · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02988843Phase 2 · terminated Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors · 167 trials list this drug (45 active) | — | — | Germ Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03356054Phase 1/Phase 2 · recruiting Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse · 167 trials list this drug (45 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01196208no longer available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02505269Phase 2 · completed Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03474133Phase 2 · unknown Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT) · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02139592completed Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01830777Phase 1 · completed Brentuximab Vedotin + Re-induction Chemotherapy for AML · 167 trials list this drug (45 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02254239Phase 1 · terminated Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02689219Phase 2 · terminated Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors · 167 trials list this drug (45 active) | — | — | Germ Cell Tumor,Embryonal Carcinoma,Malignant Testicular Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02169505Phase 2 · terminated Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03527628Phase 2 · unknown OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03440788unknown Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02729961Phase 1/Phase 2 · withdrawn Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive,Systemic Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02822586Phase 1 · completed TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome · 167 trials list this drug (45 active) | — | — | Mycosis Fungoides,Sezary Syndrome | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03373305Phase 1 · withdrawn Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas · 167 trials list this drug (45 active) | — | — | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma,Mycosis Fungoides,Sezary Syndrome+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02243436Phase 1/Phase 2 · completed Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01700751Phase 1 · completed Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation · 167 trials list this drug (45 active) | — | — | Leukemia,Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01874054Phase 1/Phase 2 · completed Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01807598Phase 2 · completed Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia · 167 trials list this drug (45 active) | — | — | Aggressive Systemic Mastocytosis,Mast Cell Leukemia,Systemic Mastocytosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01569204Phase 2 · completed Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01900496Phase 1 · terminated Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02594163Phase 2 · terminated Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02280785Phase 2 · completed Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas · 167 trials list this drug (45 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02780011Phase 1 · withdrawn Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01925612Phase 2 · terminated Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) · 167 trials list this drug (45 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03540849Phase 2 · unknown BV After Allogeneic Hematopoietic Stem Cell Transplantation · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02567851Phase 2 · completed A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01393717Phase 2 · completed Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00354107Phase 1/Phase 2 · terminated Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma,Childhood Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02280993Phase 1 · unknown Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01534078Phase 2 · completed Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02244021Phase 2 · completed BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01851200Phase 2 · completed Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors · 167 trials list this drug (45 active) | — | — | Malignant Germ Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03205891Phase 1 · withdrawn Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma,Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01309789Phase 1 · completed A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms · 167 trials list this drug (45 active) | — | — | Lymphoma,T-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02408042Phase 1/Phase 2 · withdrawn Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02423291Phase 2 · completed A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL · 167 trials list this drug (45 active) | — | — | Primary Mediastinal Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01396070Phase 2 · completed Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level · 167 trials list this drug (45 active) | — | — | Cutaneous Lymphoma,Non-Hodgkin Lymphoma,Primary Cutaneous T-Cell Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00866047Phase 2 · completed A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00848926Phase 2 · completed A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00947856Phase 2 · completed A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01841021NA · terminated Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 · 167 trials list this drug (45 active) | — | — | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01421667Phase 2 · completed A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Non-Hodgkin Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01950364Phase 1 · completed A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01461538Phase 2 · completed Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies · 167 trials list this drug (45 active) | — | — | Solid Neoplasm,Acute Lymphoblastic Leukemia,Myelodysplastic Syndrome+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01902160Phase 1 · completed Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Adult Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00337194Phase 2 · completed SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Adult Hodgkin Lymphoma,Adult Mixed Cellularity Classic Hodgkin Lymphoma,Adult Nodular Sclerosis Classic Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00099255Phase 2 · completed Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00430846Phase 1 · completed Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00649584Phase 1 · terminated A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01026415Phase 1 · completed Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) · 167 trials list this drug (45 active) | — | — | Neoplasm,Carcinoma,Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01060904Phase 1 · completed A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01026233Phase 1 · completed Cardiac Safety Study of Brentuximab Vedotin (SGN-35) · 167 trials list this drug (45 active) | — | — | Lymphoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02275598Phase 2 · unknown Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma · 167 trials list this drug (45 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00365274Phase 2 · terminated SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma · 167 trials list this drug (45 active) | — | — | Anaplastic Large Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01620229Phase 1/Phase 2 · withdrawn Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · 167 trials list this drug (45 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01671813NA · withdrawn Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly · 167 trials list this drug (45 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |